Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.01 USD
Change Today -0.06 / -0.85%
Volume 89.3K
DSCI On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ CM
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

derma sciences inc (DSCI) Snapshot

Open
$7.10
Previous Close
$7.07
Day High
$7.10
Day Low
$6.94
52 Week High
07/7/14 - $11.79
52 Week Low
05/26/15 - $6.39
Market Cap
180.4M
Average Volume 10 Days
437.2K
EPS TTM
$-1.58
Shares Outstanding
25.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DERMA SCIENCES INC (DSCI)

Related News

No related news articles were found.

derma sciences inc (DSCI) Related Businessweek News

No Related Businessweek News Found

derma sciences inc (DSCI) Details

Derma Sciences, Inc. operates as a tissue regeneration company in the wound care market. Its Advanced Wound Care segment offers MEDIHONEY dressings for managing non-chronic and hard-to-heal wounds, including chronic ulcers, burns, and post-operative wounds; TCC-EZ system for patients with diabetic foot ulcers; AMNIOEXCEL for tissue repair, reconstruction, and replacement; and AMNIOMATRIX that is used as a wound covering in the treatment of localized tissue defects. This segment also provides XTRASORB dressings, which convert fluid within the dressings to a gel and lock the exudates into the dressings; BIOGUARD dressings for prophylactic use in the prevention of hospital or community acquired infections through wound sites; ALGICELL AG antimicrobial dressings; and occlusive dressings, such as hydrocolloids, foams, hydrogels, alginates, additional silver antimicrobial dressings, cleansers, and DERMAGRAN products. The company’s Traditional Wound Care segment offers gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages, and other compression devices; adhesive bandages and related first aid products; private-label wound care products; wound closure strips, nasal tube fasteners, and catheter fasteners; and general purpose and specialized skin care products. Its Pharmaceutical Wound Care segment develops DSC127, an angiotensin analog that is in Phase III clinical trials for the treatment of diabetic foot ulcers, and preclinical testing for scar reduction. The company sells its products to various health care providers, including wound care centers, extended care facilities, acute care facilities, home health care agencies, physicians’ offices, nursing homes, hospitals, and clinics through direct sales and manufacturers’ representatives, independent distributors, and retail channels in the United States, Canada, and the United Kingdom. Derma Sciences, Inc. was founded in 1984 and is headquartered in Princeton, New Jersey.

299 Employees
Last Reported Date: 03/11/15
Founded in 1984

derma sciences inc (DSCI) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $530.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $270.0K
Executive Vice President of Operations and Ge...
Total Annual Compensation: $244.4K
Group President of Advanced Wound Care and Ph...
Total Annual Compensation: $320.0K
Group President of Traditional Wound Care and...
Total Annual Compensation: $250.0K
Compensation as of Fiscal Year 2014.

derma sciences inc (DSCI) Key Developments

Derma Sciences Inc.(NasdaqCM:DSCI) dropped from Russell 2000 Index

Derma Sciences Inc. will be removed from Russell 2000 Index

Derma Sciences Inc.(NasdaqCM:DSCI) dropped from Russell 3000 Index

Derma Sciences Inc. will be removed from Russell 3000 Index.

Derma Sciences, Inc. Announces Publication of Review of Current Clinical Development Program for aclerastide (DSC127)

Derma Sciences Inc. announced the publication of a review of the current clinical development program for aclerastide (DSC127), a patented peptide analog of angiotensin, as a potential treatment for the closure of diabetic foot ulcers (DFUs) in an article titled, 'NorLeu3-Angiotensin (1-7) [DSC127] as a Therapy for the Healing of Diabetic Foot Ulcers,' in the peer-reviewed journal, Advances in Wound Care. Aclerastide, also known as NorLeu3-A (1-7), is an analog of the active member of the RAS, A (1-7). The peptide accelerates and normalizes the healing/closure of dermal injuries in multiple animal models. In Phase I and II human clinical studies, aclerastide increased the incidence of full closure of DFUs.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DSCI:US $7.01 USD -0.06

DSCI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alliqua BioMedical Inc $5.42 USD +0.07
BioLargo Inc $0.30 USD 0.00
MiMedx Group Inc $10.87 USD -0.165
Osiris Therapeutics Inc $19.27 USD -0.29
SANUWAVE Health Inc $0.14 USD -0.035
View Industry Companies
 

Industry Analysis

DSCI

Industry Average

Valuation DSCI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.1x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DERMA SCIENCES INC, please visit www.dermasciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.